iBio, Inc., an American biotechnology company that provides contract development and manufacturing services to in the fields of biopharmaceuticals and bioprocessing.

According to the law firm press release, the lawsuit claims that iBio issued materially false and misleading statements to investors by wrongfully suggesting that iBio’s Launch platform patents and related proprietary technology would be licensed by the makers of the experimental Ebola drug ZMapp. The lawsuit claims that when the true facts were revealed, the price of iBio’s stock dropped damaging investors.

On December 16, 2015, the parties entered into a Stipulation of Settlement. This Settlement was preliminarily approved by the Court on December 22. Final approval was granted on April 21.